PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc. an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug Administration (FDA) ...

AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe AJOVY® is the first and only subcutaneous anti-CGRP treatment with both ...

The Food and Drug Administration has approved Teva’s Ajovy for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or ...

Teva Canada launches new Autoinjector for Ajovy to prevent migraine in adults AJOVY now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY ® ...

MONTRÉAL--(BUSINESS WIRE)--Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary coverage for AJOVY ® (fremanezumab) by Ontario, ...

The 3-month, randomized, placebo-controlled SPACE study enrolled 237 children and adolescents aged 6-17 years with episodic migraine. Participants were randomized to receive monthly subcutaneous ...

AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe MONTRÉAL, April 8, 2021 /CNW/ - Teva Canada, a subsidiary of Teva ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...